Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 -0.77%87 EBITDA Margin % is 21.19% as of Mar. 2026, which is 30% below its 10-year median of 30.32. GuruFocus rates BSP:BLAU3 with a GF Score™ of 87/100 and a GF Value™ of R$11.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Blau Farmaceutica ranks better than 85.3% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Blau Farmaceutica's EBITDA for the
three
months ended in Mar. 2026 was R$92 Mil. Blau Farmaceutica's Revenue for the
three
months ended in Mar. 2026 was R$435 Mil. Therefore, Blau Farmaceutica's EBITDA margin for the quarter that ended in Mar. 2026 was 21.19%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Blau Farmaceutica EBITDA Margin % Related Terms
Blau Farmaceutica EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blau Farmaceutica (BSP:BLAU3) has a EBITDA Margin % of 21.19% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Blau Farmaceutica and its competitors. This is 30% below median its historical median of 30.32. Over the past decade, Blau Farmaceutica's EBITDA Margin % has ranged from 17.19 to 38.80. According to the industry distribution chart, Blau Farmaceutica ranks #141 out of 959 companies in the Drug Manufacturers industry, placing it in the top 14.7%.
Is Blau Farmaceutica's EBITDA Margin % too high?
Blau Farmaceutica's current EBITDA Margin % of 21.19% is 30% below median its 10-year median of 30.32. Over the past 10 years, this metric has ranged from a low of 17.19 to a high of 38.80. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Blau Farmaceutica's value of 21.19% is 69.7% above this industry median. Based on the distribution chart, Blau Farmaceutica ranks #141 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #141 out of 959 companies for EBITDA Margin %. This places Blau Farmaceutica in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. Blau Farmaceutica's value of 21.19% is 69.7% above this benchmark. Historically, Blau Farmaceutica's own EBITDA Margin % has ranged from 17.19 to 38.80 over the past decade. While the company's 10-year median is 30.32 vs. the industry median of 12.49, Blau Farmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current EBITDA Margin % of 21.19% is 69.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current EBITDA Margin % is 21.19%, which is 30% below median its own 10-year median of 30.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.17, compared to a current price of R$8.98 — trading 19.6% below its estimated fair value. The current EBITDA Margin % is 21.19%, which is 30% below median its 10-year median of 30.32 and 69.7% above the Drug Manufacturers industry median of 12.49. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current EBITDA Margin % is 21.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.98 is trading 19.6% below its estimated GF Value™ of R$11.17.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
EBITDA Margin %: 21.19% (30% below median its 10-year median of 30.32)
GF Value™: R$11.17 vs. price of R$8.98 (19.6% below fair value)
Industry Position: 69.7% above the Drug Manufacturers median (#141 of 959)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score
Get the complete analysis for BSP:BLAU3
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
